PB2088: ABBV‐383 IN COMBINATION WITH ANTI‐CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION by Valdes, Cesar Rodriguez, Weisel, Katja, Baz, Rachid, Polepally, Akshanth, Ross, Jeremy A., Jin, Ziyi, D’amico, Kristin, Bueno, Orlando F., Fleming, Leanne Lash, Voorhees, Peter

Get full text

Exposure-Response Analysis Supports a Lower Dose of Venetoclax in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma Patients When Combined with Daratumumab and Dexamethasone by Badawi, Mohamed A, Engelhardt, Benjamin, Badillo, Jesus, Suleiman, Ahmed Abbas, Lash Fleming, Leanne, Luo, Yan, Kaufman, Jonathan L., Bahlis, Nizar Jacques, Menon, Rajeev, Salem, Ahmed Hamed

Get full text

Dose Escalation and Expansion of Abbv-383 in Combination with Anti-Cancer Regimens in Relapsed or Refractory Multiple Myeloma by Rodriguez, Cesar, Weisel, Katja, Baz, Rachid C., Polepally, Akshanth R., Ross, Jeremy A., Jin, Ziyi, D'Amico, Kristin, Bueno, Orlando F., Lash Fleming, Leanne, Voorhees, Peter M.

Get full text

An Updated Safety and Efficacy Analysis of Venetoclax Plus Daratumumab and Dexamethasone in an Expansion Cohort of a Phase 1/2 Study of Patients with t(11;14) Relapsed/Refractory M... by Kaufman, Jonathan L., Quach, Hang, Baz, Rachid C., Vangsted, Annette Juul, Ho, Shir-Jing, Harrison, Simon J, Plesner, Torben, Moreau, Philippe, Gibbs, Simon D., Medvedova, Eva, Jalaluddin, Muhammad, Ross, Jeremy A., Lash Fleming, Leanne, Luo, Yan, Bahlis, Nizar Jacques

Get full text

P-306 Open-Label Phase 1b Study to Evaluate the Safety and Efficacy of ABBV-383 Monotherapy in Patients With Relapsed or Refractory Light Chain Amyloidosis by Sanchorawala, Vaishali, Kumar, Shaji, Gibbs, Simon, Kastritis, Efstathios, Jaccard, Arnaud, Hoffman, David, Polepally, Akshanth, Hill, Rebecca, Fleming, Leanne Lash, Talati, Chetasi, Bueno, Orlando, Palladini, Giovanni

Get full text

Accelerating drug development in pediatric cancer: a novel Phase I study design of venetoclax in relapsed/refractory malignancies by Place, Andrew E, Goldsmith, Kelly, Bourquin, Jean-Pierre, Loh, Mignon L, Gore, Lia, Morgenstern, Daniel A, Sanzgiri, Yeshwant, Hoffman, David, Zhou, Ying, Ross, Jeremy A, Prine, Betty, Shebley, Mohamad, McNamee, Megan, Farazi, Thalia, Kim, Su Young, Verdugo, Maria, Lash-Fleming, Leanne, Zwaan, C Michel, Vormoor, Josef

Get full text

P-277 Venetoclax versus bortezomib, in combination with daratumumab and dexamethasone, in patients with t(11;14)-positive relapsed or refractory multiple myeloma by Kaufman, Jonathan, Quach, Hang, Baz, Rachid, Vangsted, Annette Juul, Ho, Shir-Jing, Abildgaard, Niels, Laubach, Jacob, Ribrag, Vincent, Gibbs, Simon, Medvedova, Eva, Voorhees, Peter, Jalaluddin, Muhammad, Zeng, Jiewei, Ross, Jeremy, Wang, Xifeng, Fleming, Leanne Lash, Bueno, Orlando, Luo, Yan, Bahlis, Nizar

Get full text

Safety and Preliminary Efficacy from the Expansion Cohort of a Phase 1/2 Study of Venetoclax Plus Daratumumab and Dexamethasone Vs Daratumumab Plus Bortezomib and Dexamethasone in... by Kaufman, Jonathan L., Quach, Hang, Baz, Rachid, Vangsted, Annette J., Ho, Shir-Jing, Harrison, Simon J, Plesner, Torben, Moreau, Philippe, Gibbs, Simon D., Medvedova, Eva, Sehgal, Vasudha, Kang, Kingston, Ross, Jeremy A., Lash-Fleming, L. Leanne, Luo, Yan, Bahlis, Nizar J.

Get full text

Impact of Number of Prior Therapies and Bulk of Disease on Outcomes with Venetoclax (VEN) Monotherapy for Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) by Wierda, William G, Seymour, John F, Roberts, Andrew W., Kim, Su Young, Lash-Fleming, L. Leanne, Maher, Johnathan, Busman, Todd, Zhou, Lang, Nielsen, Jacqueline, Stilgenbauer, Stephan

Get full text